Our previous studies evidence that adropin may offer cardioprotection against the myocardial ischemia-reperfusion injury in rodents [9] and that a low level of serum adropin may increase the risk of coronary heart disease and the severity of coronary atherosclerosis [10]. Here, ENHO is linked to coronary artery disorder.